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ABSTRACT: 
EVALUATION OF SERUM ANTICARDIOLIPIN ANTIBODY IN CHRONIC 
PERIODONTITIS PATIENTS WITH AND WITHOUT DIABETES MELLITUS 
AIMS AND OBJECTIVES: 
The aim of this present study was to evaluate serum anticardiolipin antibody (ACA) IgG 
and IgM in Chronic Periodontitis (CP) patients, Healthy controls, Type 2 Diabetes Mellitus and 
Chronic Periodontitis with Type 2 Diabetes Mellitus patients and to find out whether CP has its 
role to influence ACA levels in Type 2 Diabetes Mellitus patients. 
MATERIALS AND METHODS: 
 Venous blood samples were collected from four groups in a clean and dry tubes. Serum 
was separated and stored until analysis. Anticardiolipin antibody ELISA kit (Enzyme Linked 
Immuno Sorbent Assay) was used to assess IgG and IgM ACA levels. The results were subjected 
to statistical analysis. 
RESULTS: 
 Cardiolipin is one of the phospholipid present in the inner mitochondrial membrane. The 
results showed that ACA IgG levels were more in Chronic Periodontitis with Type 2 Diabetes 
Mellitus group compared to other three groups. The ACA IgM levels were low compared to 
other three groups. 
 
 
 CONCLUSION: 
 The results proved that CP has role to increase the ACA levels in Diabetes group and 
periodontal health is important to maintain diabetic patient’s health. Therefore, within the 
limitations of this study it can be concluded that CP is one of the risk factor for Diabetes 
Mellitus. 
 
Keywords: Anticardiolipin antibody, Type 2 Diabetes Mellitus, Chronic Periodontitis. 
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Introduction 
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Diabetes mellitus is a metabolic disorder of multiple etiology characterized by 
chronic hyperglycemia with disturbances of carbohydrate, fat, and protein metabolism 
resulting from defects in insulin secretion, insulin action or both1. It is not only 
metabolic disorder but also a vascular disease.1  
The endothelial lining of blood vessels which maintains the homeostasis 
induced by different stimuli is destructed in diabetes due to hyperglycemia, 
hyperinsulinemia, dyslipidemia and thrombotic state.1 Mitochondrial destruction of 
pancreatic islet occurs leading to β cell failure and results in the evolution of type 2 
diabetes mellitus.2 
These mitochondrial destruction also leads to the formation of anticardiolipin 
antibodies (ACA). Antibodies to cardiolipin are termed as anti-cardiolipin antibodies 
(ACA) which are the subset of anti-phospholipid antibodies.4 Cardiolipin is the major 
component of myocardium involved in oxidative respiration and electron transport 
chain.5 
Anti-phospholipid antibodies are classified as anti-cardiolipin antibodies, 
Lupus anticoagulant, beta 2 glycoprotein 1 dependent and independent IgG, IgM, IgA 
autoantibodies.4 
Anti-cardiolipin antibodies are elevated in patients with Systemic Lupus 
Erythematosus,6 Recurrent Abortions,7 Ischemic Heart Disease,8 Atherosclerosis,9 
Stroke,10 Buerger disease,11 Acute Myocardial Infarction,12 Diabetes,13 
Cardiovascular disease,14 Pulmonary disease, Rheumatoid Arthritis (RA)15 and 
Periodontitis.3  
Introduction 
  2
 The risk of Cardiovascular diseases such as atherosclerosis increases in the 
presence of Diabetes Mellitus (DM)  due to the deposition of reactive advanced 
glycation end products.16 
             Various studies have been reported linking diabetes and periodontitis 
suggesting a  bidirectional relationship and periodontitis as “sixth” complication of 
diabetes. 
Periodontitis is an inflammatory disease of tooth-supporting structures that 
leads to the destruction of connective tissue, loss of periodontal attachment and 
resorption of alveolar bone.3 It is initiated and perpetuated by a group of 
predominantly Gram-negative anaerobic microorganisms.  
Lipopolysaccharide (LPS) the outer membrane component of Gram-negative 
microorganisms is a highly potent stimulus that induces the expression of a series of 
cytokines and inflammatory mediators from host cells and causes injury to 
periodontal tissues. The microorganisms also activate cellular and humoral immune 
systems systemically. This increases the risk of systemic diseases namely Diabetes 
mellitus,3 Cardiovascular diseases, 14 Pulmonary diseases, Preterm-low-birth weight 
infants. 
The activated humoral immunity releases various antibodies against its 
antigens. These antibodies can be used as a biomarker to predict the progression of 
various systemic and periodontal diseases.17  
One such biomarker is the antibodies directed against cardiolipin, a 
phospholipid (diphosphatidyl glycerol) present in the inner mitochondrial 
membrane.17  
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              Anti-cardiolipin antibodies are elevated in periodontitis patients due to the 
molecular mimicry between the peptide sequence of arginine-gingipain protease of 
the periodontal pathogen  Porphyromonas gingivalis and  beta 2 glycoprotein 1 
(β2GP1).18 β2GP1 is a natural anticoagulant present in endothelium which prevents 
pathological prothrombotic reactions initiated by platelets or endothelial cells. ACA 
target these β2GP1 and causes arterial and venous thrombosis leading to various 
systemic sequelae of periodontitis like cardiovascular diseases.11 
The risk for cardiovascular disease in diabetes and periodontitis is more 
prevalent nowadays. In the light of the facts mentioned above, we can presume that 
ACA can be evaluated to assess the cardiovascular risks in patients with periodontitis 
and diabetes.  
 To assess the risk of cardiovascular disease or atherosclerosis in diabetic and 
Chronic periodontitis patients, the anti-cardiolipin antibodies can be evaluated. 
Therefore, the aim of this present study is to evaluate serum anti-cardiolipin antibody 
levels in Chronic periodontitis and Diabetes Mellitus and to correlate whether Chronic 
periodontitis has its effect to influence the anti-cardiolipin antibody levels in diabetic 
patients. 
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The aim of this present study is to evaluate serum anti-cardiolipin antibody 
levels in four different groups using Enzyme Linked Immuno Sorbent Assay (ELISA) 
method. The results were subjected to statistical analysis.  
The four groups are:  
       Group A: Healthy controls 
      Group B: Chronic Periodontitis      
      Group C: Type 2 diabetes mellitus 
      Group D: Chronic Periodontitis with Type 2 diabetes mellitus 
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Cardiolipin is a phospholipid present in the inner mitochondrial membrane, 
where it constitutes about 20% of the total lipid composition. The name cardiolipin is 
derived from the fact that it was first found in animal hearts.  
 Anti-cardiolipin antibodies are antibodies often directed against cardiolipin 
and found in several diseases including Antiphospholipid Syndrome,19 Behcet’s 
Syndrome, Idiopathic spontaneous abortions, Systemic Lupus Erythematosus (SLE),4 
Diabetes Mellitus,11 and  Periodontitis.3 
 Anti-cardiolipin antibodies are classified into three types10 
1. IgG 
2. IgM 
3. IgA 
Diabetes mellitus is a chronic metabolic and vascular disease.1 The endothelial 
lining of blood vessels which maintains the homeostasis induced by different stimuli 
is destructed in diabetes.1 In Diabetes mitochondrial destruction occurs.2 Therefore, 
elicits antibody response to cardiolipin. 
In periodontitis patients anti-cardiolipin antibodies are elevated.17 Periodontitis 
and Diabetes Mellitus are interrelated to each other. 
DIABETES MELLITUS IN GENERAL 
 Deedwania PC (1997)1 suggested that endothelial dysfunction is one of the 
earliest steps in the process of atherosclerosis and vascular disease. Hyperglycemia, 
hyperinsulinemia, dyslipidemia, and prothrombotic state are responsible for vascular 
damage in diabetes. Therefore, diabetic patients are more prone for atherosclerosis 
and other vascular diseases.  
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  Hoogwerf BJ (2005)20 in his review about the complications of diabetes 
found that the risk for atherosclerosis is increased in diabetes. The risk for neuropathic 
and microvascular complications is related to duration and degree of hyperglycemia. 
Retinopathy leads to blindness and the nephropathy is the leading cause of the need 
for renal replacement therapy in all diabetic patients. 
Mitra A (2008)21 analysed whether diabetes may be an outcome of stress. In 
diabetes the “fight or flight” response does not work well. Insulin is not always able to 
let the extra energy into the cells. The glucose piles up during stress because the 
insulin is not sufficient to control the blood glucose elevated by the various growth 
hormones. 
 Clayton W, Elasy TA (2009)22 studied the pathophysiology of diabetic foot 
ulcers. The causes are peripheral neuropathy and ischemia from peripheral vascular 
disease. The chemical conversion of glucose results in a depletion of nicotinamide 
adenine dinucleotide phosphate stores leading to increase in oxidative stress on the 
nerve cell and an increase in vasoconstriction. Therefore, leads to the pathogenesis of 
diabetic foot ulcers. 
 
Basta G, Schmidt M (2010)16 suggested that the formation of advanced 
glycation end products (AGEs) is an important biochemical abnormality that 
accompanies diabetes mellitus and likely, inflammation in general. AGEs potentially 
modulate initiating steps in atherogenesis involving blood vessel wall interactions, 
triggering an inflammatory-proliferative process. 
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 Yamagishi SI, Matsui T (2010)23 analysed the pathophysiologic role of AGE-
RAGE-oxidative stress in diabetic nephropathy. Inhibition of the AGE formation or 
the blockade of RAGE-downstream pathways will be a promising therapeutic strategy 
for the treatment of diabetic patients with nephropathy. 
  Ma ZA, Zhao Z, and Turk J (2012)2 identified that mitochondrial 
dysfunction is a central contributor to β- cell failure in the evolution of type 2 DM. 
Reactive oxygen species (ROS) produced by the β- cell mitochondria as a result of 
metabolic stress, activates several stress-response pathways. Therefore, in diabetes 
mitochondrial destruction occurs which leads to alterations in mitochondrial 
phospholipids. 
Chen Y,  Feng B, Li X et al. (2012)24 found that microparticles (MPs)  are  
small  membrane   vesicles shed from the plasma  membrane  surface and express a 
panel   of  phospholipids  and   proteins   specific  to  the cells from  which  they  are  
derived. MPs are associated with several cardiovascular complications. As 
multifunction biomarkers, they may contribute to the pathogenesis of diabetes 
associated vascular diseases.  
[ 
ANTI-CARDIOLIPIN ANTIBODIES IN GENERAL 
 Young CGM, Loizou S and Walport MJ (1989)19 measured the clinical, 
serological and haematological features of 20 primary APS patients. The clinical 
features are similar to that of patients with raised antiphospholipid antibodies. The 
authors concluded that “primary anti-phospholipid syndrome” can occur as a distinct 
entity. 
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Patrick H, Simpson RJ, Chesterman CN and Krilis SA (1990)25 analysed the 
binding of antiphospholipid antibodies to CL. This binding requires the presence of β2 
glycoprotein I as a cofactor.  β2GPI exerts multiple inhibitory effects on the 
coagulation pathway and platelet aggregation.   
Roubey RA (1994)26 termed anti-cardiolipin antibodies as antibodies detected 
in solid phase immunoassays, typically ELISAs, in which in the putative antigen is 
cardiolipin dried onto a microtiter plate. They are heterogenous, and include both 
antibodies to cardiolipin and cardiolipin-bound proteins. 
Cuadrado MJ, Mujic F, Munoz E et al. (1997)27 determined whether 
thrombocytopenia is associated with APS. There was no significant association 
between thrombocytopenia and clinical or serological manifestations of APS. They 
are two different clinical entities need to be considered while treating. 
 Schwarzenbacher R, Zeth K, Diederichs K et al. (1999)28 studied the crystal 
structure of β2GPI, a cofactor for phospholipid binding. The structure comprises of 
four complement control protein modules and a folding fifth C-terminal domain 
arranged as beads on a string to form elongated J shaped molecule. 
Yanez A, Cedillo L, Neyrolles O et al. (1999)29 defined antiphospholipid 
syndrome as a hemocytopenic and vasoocclusive disorder with resultant production of 
antibodies against phospholipids. The authors found that Mycoplasma pneumonia- 
induced respiratory disease produced antibodies against cardiolipin. 
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 Deguchi H, Fernandez JA, Hackeng TM et al. (2000)30 defined ACA as a 
diagnostic for phospholipid antibody syndrome which is associated with increased 
risks of venous and arterial thrombosis. They showed that epitopes of APS could 
induce CL or oxidized CL in lipoproteins or in complexes with plasma proteins or 
with platelet or endothelial surface proteins. 
Blank M, Krause I, Fridkin M (2002)31 identified a hexapeptide (TLRVYK) 
which was recognized by pathogenic anti-β2GPI monoclonal antibodies. The authors 
concluded that bacterial peptides homologous with β2GPI induces β2GPI antibodies. 
Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S (2003)32 found that 
IgM autoantibodies to malondialdehyde-modified LDL (MDA-LDL) have an inverse 
association with carotid atherosclerosis. The levels of LDL enhances atherogenesis by 
different mechanisms, which in turn complicates the risk of cardiovascular accidents. 
 
Schlame M (2008)33 found that CL is a minor component of bacterial and 
mitochondrial membranes. A sound knowledge about CL will give idea about Barth 
syndrome, cardiac myopathies and metabolic syndromes. Therefore, CL is important 
in mitochondrial organization. 
Ortana E, Cappozzi A, Colasanti T et al. (2010)34 studied the new antigenic 
target for APS patients. The authors found that vimentin act as a cofactor in 
seronegative APS patients. Therefore, suggested that vimentin act as a good tool for 
diagnosis. 
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 Osman C, Voelker DR, and Langer T (2011)5 defined mitochondria as 
dynamic organelles whose functional integrity requires a coordinated supply of 
proteins and phospholipids. Phospholipids like CL affect the stability and catalytic 
activity of mitochondrial membrane proteins. This has become the therapeutic target 
area nowadays for many diseases which affects mitochondria like diabetes mellitus.  
Pradeep Kumar, Panishankar (2011)4 quantitatively analyzed IgG and IgM 
anti-CL antibodies in 40 chronic periodontitis patients. Subjects with severe 
periodontitis exhibited marked increase in ACA IgG and IgM compared to other 
groups. A positive correlation existed between mean clinical attachment loss and IgG 
and IgM values. Severe periodontitis subjects are more prone to systemic problems 
mainly coronary heart disease. 
ANTICARDIOLIPIN ANTIBODIES AND SYSTEMIC DISEASES 
  Out HK, Groot PD, Hasselaar P, Vliet MV and Derksen R (1989)6 examined 
systemic lupus erythematosus (SLE) prospectively.  The authors found that ACA 
levels are elevated in SLE patients. Those patients are associated with recurrent or 
isolated thrombotic stroke in association with ACA.  
Coull BM, Bourdette DN, Goodnight SH et al. (1987)35 found that ACA are 
not only associated with autoimmune diseases but with infections as acute phase 
reactants. Understanding the precise role of ACA in the pathogenesis of vascular 
thromboses is important to find the mechanism of stroke.  
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Seriolo B, Accardo S, Garnero A et al. (1999)15 investigated the levels of 
protein C, S in rheumatoid arthritis (RA) patients with and without CL positivity. The 
authors found that ACA positivity and lower levels of protein S in RA patients may 
represent one of the risk factors for thrombotic events. Lower levels of free protein S 
in ACA positivity patients was involved in the pathogenesis of thrombotic events in 
SLE and autoimmune diseases. 
 Kalra S, Tuli A, Goyal U et al. (2002)7 estimated the prevalence of ACA IgM 
in patients of first trimester recurrent abortion and also the association between the 
two. 80% of patients with raised ACA antibody IgM had other infections like 
toxoplasmosis, tuberculosis. They concluded that ACA antibody was not associated 
with first trimester recurrent abortions. 
Levine JS, Branch DW, Rauch J (2002)9 reviewed about the antiphospholipid 
syndrome (APS). They found that activation of endothelial cells and oxidant mediated 
injury of endothelium and modulation of proteins involved in the coagulation leads  to 
APS. Thrombosis occurs within both venous and arterial beds. 
 Loizou S, Singh S, Wypkema E et al. (2003)36 investigated IgG, IgM, and 
IgA, antiphospholipid  antibodies (aPL), against CL, β2GPI, and  prothrombin  in 
black South African patients with infectious disease. Anti-prothrombin antibodies 
are more elevated in those patients with systemic diseases than leprosy who had 
elevated anti-β2GPI. 
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Nojima J, Masuda Y, Iwatani Y et al. (2008)8 evaluated 155 patients with 
SLE. Patients diagnosed with ASO had higher ACA/ β2GPI levels. The presence of 
ACA/ β2GPI contributes to the risk of development of ASO, which may represent an 
important mechanism for the pathogenesis of IHD in patients with SLE. 
Edwards CJ, syddall H, Jameson K et al. (2008)37 measured the ACA in  
general population. Infections in the childhood influence the ACA levels in the adult 
due to the development of immune system.  
Chen YW, Nagasawa, Ushida Y et al. (2009)10 assessed serum ACA, anti-
TLRVYK, anti-TLRIYT antibodies in 19 Buerger disease patients. Periodontopathic 
bacteria may serve as exogenous antigens that stimulate the ACA antibody production 
through molecular mimicry between the bacterial peptides and a host plasma protein. 
 
Zachman DK,  Chicco AJ, McCune SA et al. (2010)38 found that cardiac CL 
is essential for energetic. CL physically associates with cytochrome C oxidase. The 
authors developed a new method to isolate and culture CL and found that calcium 
independent phospholipase A2 is involved in the rat heart failure. 
Skare TL (2011)39 studied the ACA levels in leg ulcer patients. They found 
that ACA are elevated in patients with venous and diabetic ulcers and not in arterial 
ulcer patients. Therefore, clinical characteristics of ulcers do not identify ACA 
positivity in diabetic patients. 
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ANTI-CARDIOLIPIN ANTIBODIES AND DIABETES MELLITUS 
 Cojacaro IM, Cojacaro M, Musuroi C, Botezat M (2003)40 evaluated the 
relationship between the prevalence of the IgG anti-cardiolipin  antibodies (IgG aCL) 
and ischemic stroke in patients with diabetes mellitus. The IgG aCL titer did not differ 
significantly between patients with ischemic stroke and those without stroke. 
Therefore, the authors concluded that  IgG aCL are not a risk factor for ischemic 
stroke in diabetic patients. IgG aCL indicate inflammatory conditions in these 
pathologies. 
Tarkun I, Hacihanefioglu A et al. (2005)41 evaluated the association between 
micro and macrovascular complications of diabetes and aCL and anti-β2GPI 
antibodies. There was no association with the microvascular complications and also 
no significant association between anti- β2GPI antibodies. The authors concluded that 
there was no relation between ACA and vascular complications of DM. 
Romero J, Rodriguez E (2007)13 prospectively studied type 2 diabetes 
mellitus patients and evaluated their IgM and IgG anti-cardiolipin antibodies using 
ELISA. Low ACA titers may occur in type 2 diabetic patients and not seem to be 
associated with complicated diabetes mellitus, cardiovascular disease, nephropathy or 
retinopathy. 
Cojocaru M, Popescu L (2008)42 evaluated IgG, anti-beta 2 glycoprotein 
(anti-β2GPI) anti-cardiolipin  antibody in type 2 diabetic patients with and without 
diabetic retinopathy. The results showed that the possible participation of anti-β2GPI 
in the pathogenesis of diabetic retinopathy, shifting the homeostatic balance towards a 
pro-thrombotic state increasing the risk of developing thrombosis. 
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Ahmed E, Nittyanand S (2009)43 investigated diabetic patients with and 
without vascular complications and their ACA levels. The higher prevalence and 
levels of ACA and circulating immune complexes in patients with vascular 
complications in their study suggests that these humoral factors might be involved in 
the vascular complications of type 1 diabetes mellitus. 
Shahin M, Amany M, Diasty EL et al. (2009)44 evaluated 34 diabetics having 
proliferative diabetic retinopathy (PDR) with high risk criteria (HRC) for ACA. 6 of 
34 diabetics with PDR with HRC were positive for ACA. They concluded that 
presence of ACA may represent an additional risk factor for PDR.  
Copetti CE, Perreynoud M, Bisi MC, Staub HL (2012)45 studied the 
relationship of ACA with vascular complications of DM. A weak but statistically 
insignificant association between IgM ACA and diabetic with vasculopathy was 
found. The authors concluded that there was no association of ACA with vascular 
events in type 2 diabetes. 
PERIODONTITIS IN GENERAL 
 Armitage GC, Wu F, Wang HY, Sorrell J, Duff GW (2000) 46 classified 
periodontitis patients based on clinical attachment level as gingivitis, initial 
periodontitis, moderate periodontitis and severe periodontitis. The authors also found 
ethinic variation in the polymorphism of interleukin 1A, 1B genotype in Chinese 
populations. 
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 Hutter JW, Van der Velden U, Varoufaki A et al. (2001)47 identified lower 
numbers of erythrocytes and lower levels of hemoglobin in periodontitis patients. 
Therefore, periodontitis too needs to be considered as a chronic disease which will 
result in the reduction of number of erythrocytes and hemoglobin leading to anemia. 
Joshipura KJ, Rimm EB, Hung HC et al. (2003)48 found that periodontitis 
and few teeth are risk factors for ischemic heart disease (IHD), stroke. They 
conducted a 12 year follow up study and identified that periodontitis  patients are at 
increased risk for IHD and stroke. Patients who had periodontitis as well as few teeth 
had more risk of developing IHD compared to people with any one disease. 
Mercanoglu F et al. (2004)49evaluated whether there was endothelial 
dysfunction in patients with chronic periodontitis. The authors concluded that 
periodontitis acts as a risk factor for peripheral vascular disease and stroke. The initial 
periodontal therapy resulted in improvement of endothelial functions. Therefore, 
periodontal therapy is needed to improve not only periodontal health but also systemic 
health. 
  Rufail ML, Schenkein HA, Barbour SE et al. (2005)50 examined whether the 
increase of plasma triglycerides in generalized aggressive periodontitis (GAgP) is 
associated with changes in LDL associated platelet activating factor acetylhydrolase 
(PAF-AH) activity.  The results shown that GAgP patients have more atherogenic 
lipoprotein profile and lower PAF-AH activity. 
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Ylostala PV, Jarelin MR, Laitinen J et al. (2006)51 evaluated the risk factors 
for CVD. Dental diseases were associated with elevated total cholesterol, low HDL, 
high LDL and high leukocyte levels. The data proved that gingivitis, dental caries, but 
not tooth loss, were associated with C-reactive protein levels (CRP).  
Fentoglu O, Bozkurt FY (2008)52 found that periodontal infections causes 
bacteremia and endotoxeamia and promotes systemic immune and inflammatory 
reactions. TNF-α and IL-1β induces cytokine production which induces alteration in 
lipid metabolism. Therefore, the authors concluded that periodontal disease and 
hyperlipidemia have dual relationship. 
Wolff RE, Wolff LF, Bryan S and  Michalowicz (2009)53 assessed the 
glycosylated hemoglobin levels in periodontitis patients. The authors found a slight 
elevation in glycosylated hemoglobin. Therefore, the authors concluded that 
periodontitis is associated with elevated blood glucose in adults without diabetes and 
may increase one’s risk for type 2 DM. 
 
PERIODONTITIS AND  DIABETES MELLITUS  
Thorstensson H, Kuylenstierna J, Hugoson (1996)54 evaluated the medical 
status and complications in relation to periodontal disease experience in insulin-
dependent diabetics. The study revealed an association between renal disease, 
cardiovascular complications and severe periodontitis. 
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Preshaw PM, Alba (1999)55 suggested that there exists a clear relationship 
between the degree of hyperglycemia and severity of periodontitis. Incidences of 
macroalbuminuria and end-stage renal disease are increased twofold and threefold, 
respectively, in diabetic individuals having severe periodontitis.  
Matthew DC (2000)56 proved that the diabetes affected all periodontal 
parameters like bleeding scores, probing depths, loss of attachment and missing tooth. 
Periodontal therapy influences glycemic control in diabetic patients.  
Sadzevicienne R, Paipaliene P (2000)57 evaluated the periodontal condition in 
diabetes patients. He concluded that the increase in duration of diabetes and the 
presence of complications in other organs caused by the disease result in a more 
severe form of periodontal pathology and also the oral hygiene status affects the 
development of the inflammatory pathology of periodontal tissues. 
 
Genco J, Grossi SG et al. (2005)58  proposed a model linking inflammation to 
obesity, diabetes, and periodontal infections. They evaluated plasma levels of tumour 
necrosis factor alpha (TNF-α) and its soluble receptors (sTNFα). They concluded that 
obesity is a significant predictor of periodontal disease and insulin resistance (IR) 
appears to mediate this relationship.  
Nesse W, Linde J (2007)59 assessed the inflammatory burden using the 
periodontal inflamed surface area and HbA1C levels in type 2 diabetes. The study 
concluded a dose response relationship between blood glucose level and the amount 
of inflamed periodontal tissue in type 2 diabetes. Therefore, as the periodontal 
inflamed surface area increases the HbA1C levels also increases. 
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Engebretson S, Chertog R, Nichols A  et al. (2007)60 evaluated plasma levels 
of TNF-α in patients with chronic periodontitis and type 2 DM  and suggested that 
elevated circulating TNF-α might contribute to insulin resistance in patients with type 
2 DM. TNF was associated with more severe periodontitis and it was likely that 
periodontitis might influence circulating TNF levels.  
Tunes RS, Freitas F and Filho GH (2010)61 discussed about the impact of 
periodontal treatment in type 2 DM patients. The authors concluded that cytokine 
induced low grade inflammation in periodontitis leads to insulin resistance in 
diabetes. Therefore, periodontal treatment is mandatory to avoid cytokine induced low 
grade inflammation in diabetic patients. 
Malik G, Lehl G, Talwar M et al. (2011)62 explained the immunobiological 
association between periodontal disease and diabetes mellitus. TNFα and IL-1 
mediated insulin resistance and connective tissue destruction in periodontitis. 
Periodontal infection mediated synthesis and secretion of cytokine may amplify the 
AGE mediated cytokine response. Therefore, a dual relationship exists between DM 
and periodontitis. 
Rajhans NS, Kohad RM, Chaudhari VG and Mhaske NH (2011)63 clinically 
evaluated the relationship of diabetes mellitus with the periodontal disease. The 
prevalence of periodontal disease in diabetic patients was 86.8%. The authors 
concluded that poorer the glycemic control and longer the duration of diabetes the 
greater will be the prevalence and severity of the periodontitis. 
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Preshaw PM, Alba AL, Herrera D et al. (2012)64 suggested that susceptibility 
to periodontal disease is increased approximately by three fold in people with DM. A 
clear relationship exists between degree of hyperglycemia and severity of 
periodontitis. The mechanisms that underpin the links are not completely understood.  
PERIODONTITIS AND CARDIOVASCULAR DISEASE 
Jason L, Lavstedt S, Frithiof L et al. (2001)65 studied the relationship between 
oral health and mortality in CVD. Dental health was found to be a risk indicator of 
death due to cardiovascular disease, especially in combination with other risk factors 
like smoking habits. 
Lopez, Oyarzun, Naranjo C et al. (2002)66 evaluated Coronary Heart Disease 
(CHD) and periodontitis in Chilean adults. Hyperactive monocytes producing high 
quantities of prothrombotic cytokines when stimulated by lipopolysaccharide (LPS) 
from Gram negative oral bacteria was found. The results reflected a causal link 
between periodontal diseases and CHD. 
 Aigto F, Parkar M, Andreaou G et al. (2004)67 evaluated the association 
between periodontitis and atherogenesis and found that periodontal pathogen enters 
systemic circulation leading to various factors which increases atheroma formation. 
The authors found  that effective control of periodontal infection reduced serum 
inflammatory markers in small population with periodontitis.  
Elter JR, Champagne C, Offenbacher S and Beck JD (2004)68 evaluated the 
relationship of tooth loss and periodontitis to prevalent CHD at the atherosclerosis 
risk in communities (ARIC)  study 4. The results proved that when both tooth loss and 
periodontitis are present CHD is prevalent. 
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 Chun Y, Chun K, Olguin D et al. (2005)69 evaluated the biological 
foundation for periodontitis as a potential risk factor for atherosclerosis. P.g affected 
the vessel wall directly or indirectly via inflammatory response, immune responses, 
hemostasis. Periodontal treatment was expected to reduce the risk of atherosclerosis 
and CVD. 
Leivedaros et al. (2005)70 studied the measurements of markers of 
atherosclerosis in periodontitis. It was based on the higher intima thickness (IMT) of 
internal carotid artery (ICA) and elevated plasma levels of VWF, especially in severe 
periodontitis compared to subjects without periodontal destruction. [ 
Engebretson SP, Lamster IB, Elkind MSV et al. (2005)71 assessed whether 
chronic periodontitis was associated with atherosclerosis using panoramic 
radiographs. Periodontal bone loss is associated independently with carotid 
atherosclerosis. Panoramic radiographs may thus help to assess atherosclerosis risk in 
chronic periodontitis. 
Roth GA, Walter FR, Giacona MB et al. (2007)72 assessed the ability of P.g 
to modulate the properties of endothelial cells. Primary human aortic endothelial cells 
(HAEC) were infected with P.g strain 381. The data demonstrated that live invasive 
P.g 381 elicited a proatherogenic response in HAEC. 
Tonetti MS (2009)73 studied the relationship between periodontitis and risk for 
atherosclerosis. Periodontal pathogens were able to invade gingival tissues and gain 
access to systemic circulation.  Therefore, periodontitis causes systemic inflammation 
and endothelial dysfunction. 
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Segovia M, Reina S, Borda E et al. (2011)74 evaluated autoantibodies to β1-
adrenoceptor (β1-AR) in periodontitis patients. The authors found a decrease in heart 
rate variability (HRV) in periodontitis patients. Anti- β1-AR IgG exhibited low HRV 
and agonist like activity.  
 [ 
PERIODONTITIS AND ANTI-CARDIOLIPIN ANTIBODIES 
 Schenkein HA, Gunsolley JC, Harrison T et al. (1999)75 hypothetized that 
phosphorylcholine (PC) is an important oral antigen associated with organism in 
periodontal microflora and that anti-PC antibody is elevated as a consequence of 
periodontal disease. Therefore, periodontitis influences the anti-PC levels and in turn 
leads to systemic complications. 
Schenkein HA et al. (2003)76 evaluated ACA in sera from patients with 
Periodontitis. The prevalence of ACA was greater in CP and GAgP. There was no 
prevalence of ACA in localized AgP patients. The study indicated that the antibody 
specificity of ACA in the sera from periodontitis patients was β2GPI dependent.  
Schenkein HA (2005)18 found that P.g bears an epitope that is cross-reactive 
with β2GPI. High levels of aCL antibodies induces increased uptake of LDL into 
monocytes. This results in the formation of foam cells during early stages of atheroma 
formation. Therefore, involved in the pathogenesis of cardiovascular disease sequelae.  
Schenkein HA et al. (2007)77evaluated ACA and serum adhesion molecule 
levels in patients with AgP. Soluble intercellular adhesion molecule (sICAM-1), 
soluble vascular cell adhesion molecule (sVCAM-1) and sE-selectin were measured 
in subjects with generalized aggressive. sICAM-1 levels are  increased compared to 
other adhesion molecules in AgP.  
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 Turkoglu O, Nezihi Baris. Necil Kutukculer et al. (2008)3 in their study 
evaluated serum aCL and ox-LDL in CP patients with essential hypertension. The 
study concluded that the IgG anti-cardiolipin antibody levels were higher in 
periodontitis-hypertension group compared to that of other groups. Therefore, CP is 
involved in the elevation of ACA in Essential Hypertensive patients. 
Faghihi SH, Rokn AR, Ebrahimi R (2009)78 evaluated ACA levels in 51 
patients with moderate and advanced chronic peridontitis. Clinical parameters and 
ACA levels were assessed and there was a positive correlation between ACA levels 
and periodontal parameters.  
Karnoutosos K, Papastergiou P, Stefanidis S, Vakaloudi A (2009)79 
suggested that periodontitis can be added to the risk factors for coronary artery 
disease and atherosclerosis. Atherosclerosis have inflammatory component with 
deposition of lipids in the vessel wall. They concluded that oral bacteria from 
periodontitis can enter systemic circulation resulting in the cytokine production and 
atherosclerosis and increases aCL antibodies. 
Pereira RB, Vasquez EC, Stefanon I and Meyrelles SS (2011)80 evaluated P.g 
infection on the apo E deficient mice on the vascular permeability. The study 
demonstrated that oral P.g affects the alpha-adrenoceptor-mediated vascular 
responsiveness in both healthy and spontaneous atherosclerotic mice, reinforcing the 
association between periodontitis and cardiovascular diseases. 
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PERIODONTITIS AND CVD AND ANTICARDIOLIPIN ANTIBODY 
Muir KW(1995)14 found that IgG are elevated in the general population after 
acute stroke. The ACA levels represent an epiphenomenon of vascular endothelial and 
endomyocardial damage. Therefore, IgG ACA are involved in patients who had 
recent events of cardiac attack. 
Bili A, Moss AJ, Francis CW, Zareba W et al. (2000)81 studied the 
association of ACA with coronary artery disease. They found that elevated IgG ACA 
and low IgM ACA are independent risk factors for recurrent cardiac events. ACA 
IgM had inverse association with recurrent cardiac events. 
Mohan P, Ashok Kumar S, Geetha S et al. (2011)11 evaluated 63 patients 
with acute ST segment elevation myocardial infarction and 63 healthy controls. 
Patients with hypertension had a significant elevation of aCL antibodies. Therefore, 
Hypertension was one of the significant risk factor for AMI. 
Gunupati S, Chava VK, Phani Krishna (2011)17evaluated the effect of phase 
I periodontal therapy on ACA in patients with Acute Myocardial Infarction (AMI) 
associated with CP. Clinical parameters were measured in the baseline. Phase I 
periodontal therapy was performed and all clinical and biochemical parameters were 
reanalyzed after 1 month which resulted in altered ACA levels. Both IgG and IgM 
ACA levels were assessed and found that significant difference in IgG levels. 
Lei L, Li H, Yan F, Li Y and Xiao Y (2011)82 treated human monocytes with 
ox-LDL to induce the formation of foam cells. P.g altered atherosclerotic related gene 
expression in oxidized LDL induced macrophages and foam cells. They concluded 
that P.g LPS appears to be an important factor in the development of atherosclerosis 
via activation of NFκB pathway. 
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For the present cross sectional study,  four groups comprising of 68 patients 
were selected and the levels of serum anticardiolipin antibody IgG and IgM were 
evaluated. The four  study groups  were: Group A: Healthy, Group B: type 2 Diabetes 
Mellitus, Group C: Chronic Periodontitis, Group D: Chronic Periodontitis with type 2 
Diabetes Mellitus.  
The patients were selected  based on Armitage classification (2000)41 for 
Chronic Periodontitis and for type 2 Diabetes mellitus based on blood glucose profile 
with random blood glucose level > 126 mg/dl (WHO) criteria.  The patients were 
selected from diabetes centre and J.K.K. Nattraja Dental College and Hospital, 
Komarapalayam using the following selection criteria. 
Inclusion Criteria: (for all groups) 
1) Periodontally and systemically healthy patients. 
2) Chronic periodontitis patients who are systemically healthy. 
3) Individuals with type 2 diabetes mellitus. 
4) Chronic periodontitis with type 2 Diabetes mellitus. 
5) Individuals with > 16 teeth present. 
6) Mean Clinical attachment level greater than 2.5 mm. 
7) Both male and female patients. 
Exclusion Criteria:  
1) Patients with systemic illness other than type 2 diabetes mellitus. 
2) Subjects with vascular complications of diabetes mellitus. 
3) Subjects who underwent periodontal treatment during the last 6 months 
period. 
Materials & Methods 
  25
4) Subjects under antibiotic coverage within the past 6 months. 
5) Subjects with known history of anti-phospholipid syndrome. 
6) Subjects with known history of autoimmune diseases. 
7) Smokers, alcoholic and pregnant women. 
Study design: 
Group A: Healthy controls, Group B: Chronic Periodontitis, Group C: type 2 
diabetes mellitus, Group D: Chronic Periodontitis with type 2 Diabetes mellitus. 
    Group A                   Group B        Group C                 Group D  
       n=17     n=17  n=17           n=17 
 
                                    
ACA IgG and IgM      Excluded n=0 
         analysed using ELISA 
  
The nature and design of the study were explained to the patients and consent 
were obtained for their participation. 
 Patients included in the study were screened using mouth mirror and 
periodontal probe. All patients underwent periodontal evaluation, haematological and 
biochemical analysis. Clinical  periodontal parameters were calculated as follows. 
Clinical parameters 
The following variables were measured. 
1. Gingival index 
2. Plaque index 
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3. Oral hygiene index 
4. Probing pocket depth 
5. Clinical attachment level 
1) Gingival index: ( Loe H and Silness P. 1963) 
The soft tissue surrounding each tooth were divided into 4 gingival scoring units i.e. 
the distofacial papilla, the facial margin, the mesiofacial papilla and the entire lingual 
margin. A periodontal probe was used to assess the bleeding of the gingival tissues on 
probing. 
Gingival units were assessed according to the following criteria: 
0-   Normal gingival 
1- Mild inflammation, slight change in colour, no bleeding on palpation. 
 
2- Moderate inflammation, redness, edema & glazing, bleeding on probing. 
3- Severe inflammation, marked redness & edema, ulceration, tendency for 
spontaneous bleeding. 
The gingival index score for each of the 4 gingival surfaces was given a score 
from 0 to 3. The scores around each tooth were totaled and divided by four and the 
gingival index score for each tooth was obtained. 
The scoring criteria are as follows 
0.1-1.0 – Mild 
                1.1-2.0 – Moderate 
                 2.1-3.0 – Severe 
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2) Plaque index: (Silness P and Loe H. 1964, modified by Loe H. 1967) 
0- No plaque in the gingival area. 
1-   A film of plaque adhering to the free gingival margin and adjacent area of 
the tooth. The plaque may be recognized only by running a probe across the 
tooth surface. 
2- Moderate accumulation of soft deposits within the gingival pocket or on the 
gingival margin & adjacent tooth surface. 
3- Abundance of soft matter within the gingival pocket or on the gingival 
margin & adjacent tooth surface.                                                                                          
[ The areas examined were the distofacial, facial, mesiofacial and lingual 
surface using explorer. The plaque score was obtained by totaling the four plaque 
scores per tooth and then divided by four. The plaque score per person is obtained by 
adding the plaque score per tooth and dividing by the number of teeth examined. 
3) Oral Hygiene index: (Simplified) [Greene and Vermillion 1964]: 
 The six tooth surfaces were examined. Facial surface of 16,11,26,31 and 
lingual surface of 36, 46 were examined using an explorer. 
Debris index (DI-S) 
 Dental explorer was placed on the incisal third of the tooth and moved towards 
the gingival third of the tooth. 
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The scoring criteria is 
0- No debris or stain present 
1-  Soft tissue covering not more than 1/3rd of the tooth surface or the 
presence of extrinsic stains without other debris, regardless of surface area 
covered. 
2-  Soft debris covering more than 1/3rd but not more than 2/3rd of exposed 
tooth surface. 
3-  Soft debris covering more than 2/3rd of the exposed tooth surface. 
DI-S score per person is obtained by totaling the debris score per tooth surface 
divided by number of surfaces examined. 
Calculus index: (CI-S) 
 Assessed by placing a dental explorer into the distal gingival crevice and 
drawing it subgingivally from distal contact area to the mesial contact area. 
0- No calculus present 
1-  Supragingival calculus covering not more than 1/3rd of the exposed tooth 
surface 
2- Supragingival calculus covering more than 1/3rd of the exposed tooth surface 
but not more than 2/3rd of the exposed tooth surface or the presence of 
individual flecks of subgingival calculus around the cervical portion of the 
tooth or both. 
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3- Supragingival calculus covering more than 2/3rd of the exposed tooth surface 
or a continuous heavy band of subgingival calculus around the cervical 
portion of the tooth or both. 
Good – 0.0-0.6 
Fair   –  0.7-1.8 
Poor –   1.9-3.0 
The OHI-S score per person is the total of DI-S and CI-S scores per person. 
The scoring criteria are as follows 
0.0-1.2 - Good  
1.3-3.0 – Fair 
3.1-6.0 – Poor 
4) Probing pocket depth: 
 The depth of the pocket was measured at four sites per tooth excluding the 
third molars using periodontal probe. The probe was inserted parallel to the long axis 
of the tooth gently, until resistance was felt and the readings were recorded to the 
nearest millimeter from the gingival margin to the base of the pocket. 
5) Clinical attachment level: 
 The level of attachment is the distance between the base of the pocket and 
Cementoenamel junction (CEJ) or a fixed point. The distance from the CEJ ( if CEJ is 
not detected, the coronal border of the stent was used) to the base of the pocket was 
measured. The readings were recorded to the nearest millimeter. 
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Table top Centrifuge Machine 
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ACA IgG test kit 
 
ACA IgM test kit 
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LABORATORY METHODS 
 Sample Collection: 
  2ml venous blood was obtained from each subject in the morning from the 
ante cubital fossa using 2 ml sterile disposable syringe with 23 gauge needle. The 
blood was then transferred to empty sterile vacutainer and transported to the clinical 
laboratory for analysis of ACA IgG and IgM. 
Estimation of ACA: 
All blood samples were analysed in the same laboratory using enzyme linked 
immunosorbent assay (ELISA). Standard serum were used to measure the anti-
cardiolipin antibody IgG normal range: < 23 GPL units / ml and IgM  normal range < 
11 MPL units / ml using REALISA anti-cardiolipin IgG and IgM ELISA kit. IgG 
levels were measured in GPL units and IgM levels were measured in MPL units.  
Sample storage: 
 Blood samples were collected in clean, dry and empty tubes. After separation, 
the serum samples were stored at -40C upto three days.  
Principle of the assay: 
Purified Cardiolipin antigens are coated on the surface of microwells. Diluted 
patient serum or plasma, and calibrators, are added to the wells. The Anti-cardiolipin 
specific antibodies, if present, bind to the antigens.  
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All unbound materials are washed away. After adding enzyme conjugate, it 
binds to the antibody-antigen complex. Excess enzyme conjugate is washed off, and 
TMB Chromogenic substrate is added. The enzyme conjugate catalytic reaction is 
stopped at a specific time. The intensity of the color generated is proportional to the 
amount of IgG specific antibodies in the sample. The results are read by a microwell 
reader, and compared in a parallel manner with calibrators. 
                                         ELISA READER  
 
   
  Prepare a 1:101 dilution of the patient samples by mixing 5 µl of the 
patient sera with 500ul of Serum Diluent. Incubate 30 minutes (± 5 min) at 
room temperature.  Wash  4x  with  wash  buffer.  Pipette 100 µl of Conjugate 
into microwells. Incubate 30 minutes (± 5 min) at room temperature.  
 [ 
QUALITATIVE DETERMINATION 
Abs. of Test Sample 
---------------------------- X     Units of Calibrator D =  Units of Test  sample 
Abs. of Calibrator D 
 
Qualitative results are reported as “positive” or “negative.” Sample results 
greater than or equal to Calibrator D are considered positive. 
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Purified Cardiolipin antigens are coated on the surface of microwells. Diluted 
patient serum or plasma, and calibrators, are added to the wells. The Anti-Cardiolipin 
specific antibodies, if present, bind to the antigens. All unbound materials are washed 
away. After adding enzyme conjugate, it binds to the antibody-antigen complex. 
Excess enzyme conjugate is washed off, and TMB Chromogenic substrate is added.  
ELISA WASHER 
 
 
 
The enzyme conjugate catalytic reaction is stopped at a specific time. The 
intensity of the color generated is proportional to the amount of IgM specific 
antibodies in the sample. The results are read by a microwell reader, and compared in 
a parallel manner with calibrators. 
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APPENDIX – I 
PROFORMA 
PATIENT NAME:      OP.NO: 
AGE:        SEX: 
ADDRESS:       PHONE NO: 
CHIEF COMPLAINT: 
PAST MEDICAL HISTORY: 
KNOWN DIABETIC: 
  YES     NO      
DURATION OF DIABETES: 
 
CONTROLLED/UNCONTROLLED DIABETIC: 
HbA1C    : 
 
PRESENT MEDICAL HISTORY: 
 
DRUG HISTORY: 
 
PAST DENTAL HISTORY: 
 
PRESENT DENTAL HISTORY: 
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INDICES 
GINGIVAL INDEX: 
BASELINE:      Maxilla 
                     
              
       7        6          5        4        3        2        1        1         2         3          4       5          6         7   
                     
              
         
                                                            Mandible                          Score: 
PLAQUE INDEX: 
BASELINE:                                         Maxilla 
 
                    
              
         7        6          5         4       3          2          1      1        2         3          4       5         6         7   
                    
              
                                           
                                                       Mandible                            Score: 
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   [ 
ORAL HYGIENE INDEX (SIMPLIFIED): 
 
DEBRIS INDEX (DI-S): 
 
          
16 11 26 36 31 46 
                         
 
CALCULUS INDEX (CI-S): 
OHI-S = CI-S + DI-S 
INTERPRETATION:                                                                                        
 
PROBING  POCKET DEPTH: 
Maxilla 
        
                    
              
         7        6          5         4       3          2          1      1        2         3          4       5         6         7   
                    
              
  
     Mandible      
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CLINICAL ATTACHMENT LEVEL: 
Maxilla 
         
        
                    
              
         7        6          5         4       3          2          1      1        2         3          4       5         6         7   
                    
              
 
                    Mandible 
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APPENDIX – 2 
ARMAMENTARIUM 
1. Mouth mirror 
2. Explorer 
3. Periodontal probe 
4. Sterile cotton rolls 
5. Kidney tray 
6. Gloves 
7. Patient apron 
8. Head cap 
MATERIALS USED FOR SERUM PREPERATION 
1. 10 ml syringe 
2. Tourniquet 
3. Pipettes 
4. Test tubes 
5. Centrifuge 
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INFORMED CONSENT OBTAINED FROM THE PATIENT: 
DEPARTMENT OF PERIODONTICS, J.K.K. NATTRAJA DENTAL COLLEGE, 
KOMARAPALAYAM, NAMAKKAL DISTRICT. 
PATIENT NAME: 
I have been explained about the nature and purpose of the study in which, I 
have been asked to participate. I understand that I am free to withdraw my consent 
and discontinue at any time without prejudice to me or effect on my treatment. 
I have been given the opportunity to question about the material and study. I 
have also given the consent for photographs to be taken at the beginning, during and 
end of the study. I agree to participate in this study. 
I hereby give the consent to be included in “Evaluation of serum anti-
cardiolipin antibody in chronic periodontitis patients with and without diabetes 
mellitus”. 
 
 
Station:                                                                           SIGNATURE OF PATIENT 
 
 
Date:                                                                         SIGNATURE OF PROFESSOR 
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STATISTICAL ANALYSIS 
ANOVA (Analysis of Variance)  
 
 Analysis of variance refers to the examination of differences among the 
samples. It is used to examine the significance of the difference amongst more than 
two sample means at the same time. The term ANOVA was first proposed by 
R.A.Fisher. The method consists of classifying and cross-classifying statistical results 
and testing whether the means of specific classification differ significantly. 
All the statistical methods were carried out through the SPSS for Windows 
(Version 16.0) 
A total of 68 patients were selected and their serum levels of ACA IgG and 
IgM were analysed using ELISA test and compared using ANOVA. 
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A total of 68 patients  with 17 patients in each group were selected in this 
present study.  The biochemical parameters of ACA IgG were shown in the Table and 
Graph  No. 1.  The mean serum levels of ACA IgG of group A was 3.47 ±0.36. The 
mean serum levels of ACA IgG of group B was 5.33±0.523 and group C was 
4.35±1.12 and group D was 6.13±0.61. No patient had ACA IgG positivity. 
The biochemical parameters of ACA IgM were shown in the Table and Graph 
No.2. The mean serum levels of ACA IgM of group A was 3.26±0.70. The mean 
serum levels of ACA IgM of group B was 1.96±0.90 and group C was 3.47±0.06 and 
group D was 2.32±0.81. Only one patient had ACA IgM (>11 MPL units/ml) 
positivity. 
There was a significant difference (P<0.05) in the serum ACA IgG between 
group A (3.47 ±0.36) and group B (5.33±0.523) as shown in the Table and Graph 
No.3. There was a statistically significant difference between group A (3.47 ±0.36) 
and group C (4.35±1.12).  and between group A (3.47 ±0.36) and group D 
(6.13±0.61) as shown in the Table  and Graph No.3. 
There was a statistically significant difference (P<0.05) in the serum ACA 
IgM between group A (3.26±0.70) and group B (1.96±0.90) as shown in the Table 
and Graph No.4. There was no statistically significant difference (P>0.05) between 
group A (3.26±0.70) and group C (3.47±0.06) and between group A (3.26±0.70) and 
group D ((2.32±0.81) as shown in the Table  and Graph No.4. 
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The intragroup comparison of serum ACA IgG and IgM of group A shows a 
statistically significant difference (P<0.05) as shown in the Table  and Graph No.5. 
The intragroup comparison of ACA IgG and IgM of group B, C, D showed a 
statistically significant difference (P<0.05) as shown in the Table  and Graph No.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
TABLES 
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TABLE – 1 
Mean ACA IgG titer of all study groups 
 
S.No Parameters ACA IgG titer 
1 Group A 3.47±0.36 
2 Group B 5.33±0.53 
3 Group C 4.35±1.12 
4 Group D 6.13±0.61 
 
 
ACA – Anti-Cardiolipin Antibody 
TABLE – 2 
Mean ACA IgM titer of all study groups 
S.No Parameters ACA IgM titer 
1 Group A 3.26±0.70 
2 Group B 1.96±0.90 
3 Group C 3.47±0.06 
4 Group D 2.32±0.81 
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TABLE – 3 
Comparison of mean ACA  IgG  of  Group A with other three groups 
S.No Parameters ACA IgG titer P value < 0.05 
1 Group A vs Group B 3.47±0.36 Vs 5.33±0.53 0.029* 
2 Group A vs Group C 3.47±0.36 Vs 4.35±1.12 0.000* 
3 Group A vs Group D 3.47±0.36 Vs 6.13±0.61 0.000* 
       
            Significant* (P<0.05) 
 
            TABLE – 4 
Comparison of mean ACA IgM of Group A with other three groups 
S. 
No 
Parameters ACA IgM titer P value < 0.05 
1 Group A Vs   Group B 3.26±0.70  Vs   1.96±0.90 0.037* 
2 Group A Vs   Group C 3.26±0.70  Vs    3.47±0.06 0.370 
3 Group A Vs   Group D 3.26 ±0.70   Vs     2.32±0.81 0.490 
 
  
Significant* (P<0.05) 
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TABLE – 5 
Intragroup comparison  of ACA IgG and IgM of all study groups 
S.No Parameters 
 
ACA IgG titer
 
ACA IgM titer P value < 0.05 
1 Group A 3.47 ±0.36 3.26±0.70 0.0001* 
2 Group B 5.33±0.53 1.96±0.9 0.0390* 
3 Group C 4.35±1.12 3.47±0.06 0.0001* 
4 Group D 6.13±0.61 2.32±0.81 0.0001* 
 
  Significant * (P<0.05) 
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     GRAPH - 1 
Comparison of mean ACA IgG of all study groups 
 
                 GRAPH- 2 
                     Comparison of mean ACA IgM of all study groups 
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GRAPH – 3 
                  Comparison of ACA IgG of group A with other three groups 
      
              
GRAPH –4 
Comparison of ACA IgM of Group A with other three groups 
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GRAPH - 5 
Comparison of mean ACA IgG and IgM of all study groups 
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Diabetes Mellitus is a metabolic disorder of multiple etiology characterized by 
chronic hyperglycemia with disturbances of carbohydrate, fat, and protein metabolism 
resulting from defects in insulin secretion, insulin action or both3.  
DM is proved to be the risk factor for periodontitis and cardiovascular 
diseases. Type 2 DM patients who have uncontrolled blood glucose levels are more 
prone for periodontal destruction. It is proved that periodontal health improved the 
metabolic control of type 2 DM patients.  
Periodontitis and cardiovascular diseases are closely related as both are 
chronic inflammatory disease and atherosclerosis which is a focal thickening of the 
arterial intima and media is the major cause of death in all cardiac patients. 
Cardiolipin one of the phospholipid present in the inner mitochondrial 
membrane elicits antibody response in DM patients due to mitochondrial destruction1. 
It is also elevated in acute myocardial infarction, other systemic infections and also in 
periodontitis3. 
Anti-cardiolipin antibodies are autoantibodies directed against cardiolipin, a 
phospholipid. These antibody levels are elevated in periodontitis3, diabetes13, 
infections and cardiovascular diseases14. The ACA IgG and IgM levels are evaluated 
in four different groups namely: Group A: Healthy controls, Group B: Chronic 
Periodontitis, Group C: Type 2 Diabetes Mellitus, Group D: Chronic Periodontitis 
with type 2 Diabetes Mellitus. 
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When IgG ACA levels were compared between group A (3.47±0.36) and 
group B (5.33±0.53), the levels were significantly elevated in group B (P<0.05). The 
same results were obtained by Schenkein HA et al.85 who found that the prevalence of 
ACA were higher in chronic periodontitis patients when compared with healthy 
patients as the severity and the extent of inflammation were more in periodontitis 
patients. 
When IgG ACA levels were compared between group A (3.47±0.36) and 
Group C (4.35±1.12), the levels were significantly elevated in group C (P<0.05). The 
results  obtained in this present study were in accordance with the study done by 
Romero J et al.13 who found that  low ACA IgG and IgM may occur in type 2 diabetic 
patients.  
 When IgG ACA levels were compared between group A (3.47±0.36) and 
group D (6.13±0.61), the levels were significantly higher in group D (P<0.05). The 
probable reason may be due to the presence of both systemic (DM) and local infection 
(Periodontitis) which together caused this elevation of ACA IgG levels. The elevated 
IgG titer leads to systemic thrombotic events as shown by Kalra S et al.7 
When IgM ACA levels are compared between group A (3.26±0.70)  and group 
B (1.96±0.90), the levels were significantly lower in group B (P < 0.05). The similar 
type of results were obtained by Schenkein HA et al.84 who found that ACA levels 
were elevated in Periodontitis patients due to the presence of phosphorylcholine 
containing antigen in oral species compared to the healthy patients. 
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When IgM ACA levels are compared between group A (3.26±0.70) and group 
C (3.47±0.06), the levels were not significantly lower in group C (P>0.05).  
In this present study the IgM ACA levels when compared between group A 
(3.26±0.70) and group D (2.32±0.81), the levels were not significantly lower in group 
D (P>0.05). This could be probably due to the reason that IgM had inverse association 
with the severity of cardiac events according to Bili et al.81 who found that elevated 
IgM were not associated with any systemic complications.  According, to the authors 
IgM ACA represent protective natural autoantibodies or they have rheumatoid factor 
activity and thus play a beneficial role in immune homeostasis. Therefore, the ACA 
IgM levels which were high in Group A  proves that these patients are not prone for 
cardiac events but  in group D  more prone for cardiac events. 
The above results indirectly proves the relationship that group D who had high 
levels of  IgG and low levels of IgM are more prone for cardiac diseases like 
atherosclerosis, stroke and thrombosis. Therefore, chronic periodontitis may be one of 
the risk factor for elevating the ACA levels in these groups of patients.  
Based on the above results, Chronic Periodontitis not only causes lipid 
abnormality and hyperglycemia but also elevates anti-cardiolipin antibody levels in 
diabetic patients which was proved in this present study. 
Generally, it is well known that ACA assay when employed in the cases of 
recurrent abortions, CHD, Stroke, Syphilis, Atherosclerosis it is found to be elevated. 
Likewise, in this present study when ACA assay were employed in type 2 Diabetic 
patients, it were found to be in low titer, whereas in Chronic Periodontitis patients it 
were found to be moderately increased.  
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 But in Chronic Periodontitis with type 2 Diabetes Mellitus group, ACA levels 
were significantly elevated (P<0.05) compared to healthy controls. Ultimately the 
contribution of Chronic Periodontitis decides the increase in the levels of 
anticardiolipin antibodies in diabetic patients. 
           However, the limitations of this present study were small sample size, no 
follow up of cases and there was no periodontal treatment done to find out the 
influence of periodontal treatment on the levels of anticardiolipin antibodies.  
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 The aim of the present study was to evaluate the ACA levels in four different 
groups and also to find out whether Chronic Periodontitis has any role to play and 
influence on the levels of ACA in diabetic patients. 
The anti-cardiolipin antibody levels (IgG and IgM) were measured using 
Enzyme Linked Immuno Sorbent Assay (ELISA). The levels were subjected to 
statistical analysis and compared using ANOVA (analysis of variance).  
From the results obtained, the following conclusions were arrived: 
* Chronic Periodontitis with type 2 Diabetes Mellitus group had elevated 
levels of IgG ACA compared to that of Chronic Periodontitis group, Type 2 Diabetes 
Mellitus group and Healthy controls. Therefore, Chronic Periodontitis may act as an 
additional risk factor in diabetic patients to increase the ACA levels.  
* The IgM ACA levels were low in Chronic Periodontitis with type 2 Diabetes 
Mellitus group which proves that these groups are more prone for cardiac 
thrombosis. IgM have inverse association with cardiac events17. 
In the light of the facts mentioned above, Chronic Periodontitis can be 
considered as a risk factor for diabetic patients to develop cardiovascular 
complications.  
The results of the present study have proved that a strong and definite 
association exists between periodontal diseases and systemic diseases.  Periodontal 
disease will contribute directly to the pathogenesis of atherosclerosis by providing 
persistent bacterial challenges.  
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The anticardiolipin antibody assay employed in this study can be utilized as a 
biomarker for assessing the risk of the patients (in general) like Diabetes Mellitus, 
Atherosclerosis, Stroke and also the risk of Periodontitis patients (in particular) for 
developing systemic diseases. 
Any research study is bound to be questioned in respect of various factors 
such as anamolies, presumptions, leniences, environmental differences, etc., 
Similarly, this study also has some limitations. In order to overcome those limitations 
to some extent, a large sample size with regular follow up accompanying periodontal 
treatment can better discover the relationship among periodontitis, anticardiolipin 
antibody and systemic diseases. 
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